platelet P-selectin and tumor cell sialylated mucins that has been shown to be essential for metastatic spread in mouse models (17). Finally, the findings of Boucharaba et al. lay the groundwork to suggest that inhibition of platelet-derived LPA action on its cognate receptors expressed by tumor cells may be another promising therapeutic target, especially for bone metastasis. The development and clinical testing of this class of specific modulators of platelet function will be necessary before a verdict can be reached regarding the importance of platelets in the progression of disease in cancer patients.

Address correspondence to: Joan Massagé, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 116, New York, New York 10021, USA. Phone: (212) 639-8975; Fax: (212) 717-3298; E-mail: j-massague@ski.mskcc.org.


The Staphylococcus aureus “superbug”

Timothy J. Foster

Microbiology Department, Mayone Institute of Preventive Medicine, Trinity College, Dublin, Ireland.

There has been some debate about the disease-invoking potential of Staphylococcus aureus strains and whether invasive disease is associated with particularly virulent genotypes, or “superbugs.” A study in this issue of the JCI describes the genotyping of a large collection of nonclinical, commensal S. aureus strains from healthy individuals in a Dutch population. Extensive study of their genetic relatedness by amplified restriction fragment typing and comparison with strains that are associated with different types of infections revealed that the S. aureus population is clonal and that some strains have enhanced virulence (see the related article beginning on page 1732). This is discussed in the context of growing interest in the mechanisms of bacterial colonization, antibiotic resistance, and novel vaccines.

Nasal colonization

Staphylococcus aureus is a common commensal of humans and its primary habitat is the moist squamous epithelium of the anterior nares (1). About 20% of the population are always colonized with S. aureus, 60% are intermittent carriers, and 20% never carry the organism. As there is considerable evidence that carriage is an important risk factor for invasive infection (1, 2), it is surprising that so little is known about the bacterial factors that promote colonization of squamous epithelial surfaces and the host factors that determine whether an individual can be colonized or not.

Methicillin-resistant S. aureus

Healthy individuals have a small but finite risk of contracting an invasive infection caused by S. aureus, and this risk is increased among carriers. Hospital patients who are catheterized or who have been treated surgically have a significantly higher rate of infection. In some, but not all, developed countries, many nosocomial infections are caused by S. aureus strains that are multiply resistant to antibiotics — known as methicillin-resistant Staphylococcus aureus (MRSA) (3, 4) — although the acronym MRSA is somewhat misleading because the semisynthetic β-lactam methicillin is no longer used to treat S. aureus infections. In MRSA, the horizontally acquired mecA gene encodes a penicillin-binding protein, PB2a, which is intrinsically insensitive to methicillin and all β-lactams that have been developed, including the isoxazolyl penicillins (e.g., oxacillin) that superceded methicillin, in addition to the broad spectrum β-lactams (third-generation cephalosporins, cefamycins, and carbapenems) that were introduced primarily to treat infections caused by Gram-negative bacteria (4) (Figure 1). In contrast to nosocomial MRSA strains, which are usually multidrug resistant, the recently emerged community-acquired MRSA (CA-MRSA) strains are susceptible to drugs other than β-lactams (5). Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73:321–354.
The term MRSA is synonymous with multidrug-resistant *S. aureus* because many nosocomial MRSA strains are resistant to most commonly used antibiotics. The glycopeptide vancomycin was the last available drug to which this organism had remained uniformly sensitive until recent reports of low-level glycopeptide resistance (6) and, very recently, the transfer of high-level vancomycin resistance from *Enterococcus* to *S. aureus* (7). Although new drugs, including lincosamid and synercid, have recently been introduced to treat MRSA infections (8), there is a worrying lack of novel drugs in the pipeline.

**Virulence factors**

*S. aureus* strains can express a wide array of potential virulence factors (Figure 1), including surface proteins that promote adherence to damaged tissue (9), bind proteins in blood to help evade antibody-mediated immune responses (9), and promote iron uptake (10). The organism also expresses a number of membrane-damaging toxins and superantigen toxins that can cause tissue damage and the symptoms of septic shock, respectively (11). There is a growing realization that *S. aureus* has multiple mechanisms for evading both innate immunity mediated by polymorphonuclear leukocytes (12, 13) and induced immunity mediated by both B and T cells (11, 14). Some virulence factors are expressed by genes that are located on mobile genetic elements such as the chromosomal genes that encode PVL (16), a toxin that is strongly associated with severe skin infections (19).

**Evidence for clones with enhanced virulence**

Melles et al. (17) also examined a smaller number of isolates from individuals with invasive disease (bacteremia and deep-seat ed abscesses) as well as those from individuals with severe impetigo. There was clear evidence that some clonal types are more virulent than others in that they appeared more frequently among disease isolates than among carriage isolates (Figure 2). This sharply contrasts with the earlier Oxfordshire study, in which no evidence for hypervirulent clones was found (18). In the Melles et al. study, bacteremia in elderly patients was significantly more frequently caused by 1 strain in cluster IVa (17). In addition, strains causing severe skin infections were significantly more frequently found to be members of cluster IVa. This could be due to lysogenization of a progenitor IVb strain with the bacteriophage that encodes PVL (16), a toxin that is strongly associated with severe skin infections (19).

The question remains: Why did this study find evidence for virulent clones, whereas the Oxfordshire study did not? Perhaps this discrepancy can be attributed to the fact that Melles et al. tested a larger number of strains (17). Furthermore, the Oxfordshire study (18) was confined to isolates obtained from patients with invasive infec-
Evolution of MRSA

MRSA strains have emerged by acquisition of mobile genetic elements called SCCmec cassettes, which carry the mecA gene that encodes PBP2a. There are 5 different cassettes (SCCmec types I–V; refs. 3, 20, and 21). It is now clear that major MRSA clones were created on multiple occasions by acquisition of SCCmec by prevalent strains that have continued to flourish (22). None of the Dutch carriage or invasive strains isolated from Dutch individuals, none were identified as MRSA. This is consistent with the conclusion that all strains of S. aureus have the potential to cause infection and that some are more virulent than others.

Future prospects for combating S. aureus

Given the problems caused by the development of antibiotic-resistant S. aureus, vaccination may well have a significant role to play in controlling this organism in the future. A number of companies are developing products intended for active or passive immunization against S. aureus infections, including a capsular polysaccharide vaccine that has been subjected to a clinical trial with hemodialysis patients (24), a monoclonal antibody (25), and human immunoglobulin that is enriched for antibodies that recognize clumping factor A (26).

An increased understanding of how S. aureus colonizes the nares could allow improved methods for controlling nasal and skin carriage. Recent studies of mutant strains defective in wall teichoic acid (WTA) in a rat model of nasal colonization implicated WTA in colonization (27). Also, several different surface proteins can promote adherence of S. aureus to squamous epithelial cells isolated from the nares (28, 29) and could act as adhesins involved in nasal colonization. Another mystery that deserves greater attention is the question of why some members of the population never carry S. aureus, while others are persistent carriers.

The study by Melles et al. (17), in combination with MLST analysis (18), provides a solid foundation for analysis of novel hypervirulent or epidemic drug-resistant S. aureus clones that might arise in the future. One thing seems certain: S. aureus will continue to respond to challenges imposed by humans’ continued attempts to combat its carriage and development of related disease.

Address correspondence to: Timothy J. Foster, Microbiology Department, Maynooth Institute of Preventive Medicine, Trinity College, Dublin 2, Ireland. Phone: 353-1-6082014; Fax: 353-1-6799294; E-mail: tfoster@tcd.ie.

Acid sensing in renal epithelial cells

Stephen L. Gluck

Division of Nephrology, UCSF, San Francisco, California, USA.

The kidney adjusts net acid excretion to match production with exquisite precision, despite little or no change in the plasma bicarbonate concentration. The acid-sensing pathway that signals the kidney to increase acid secretion involves activation of the proto-oncogene c-Src. A new study in this issue shows that proline-rich tyrosine kinase 2 (Pyk2) is responsible for acid-induced activation of c-Src and is essential for acid sensing in renal epithelial cells (see the related article beginning on page 1782). The findings implicate a broader role for Pyk2 in acid-base homeostasis in bone and other tissues beyond the kidney.

Although the principal product of metabolism in mammalian cells is the volatile acid carbon dioxide, humans on a typical Western diet produce about 70 millimoles of nonvolatile acid per day. Remarkably, varying metabolic acid production over a range of 0–150 millimoles is accompanied by a matching increase in net acid excretion by the kidney with a change of only 1 mM in plasma bicarbonate concentration (1). The adaptive responses that enable the kidney to increase net acid excretion in response to increased acid generation have been studied extensively in animal models of metabolic acidosis. In the proximal tubule, acidosis increases the activity of luminal and basolateral proteins involved in bicarbonate transport (2, 3), ammonia generation (4), and the reabsorption and metabolism of citrate (5). In the collecting duct, acidosis suppresses bicarbonate secretion (6) and stimulates recruitment of proton pumps to the luminal membrane of intercalated cells (7). Of the acid-base transporters in the proximal tubule, the luminal sodium/hydrogen exchanger 3 (NHE3) has a prominent role, and the mechanism by which its activity increases during metabolic acidosis has been examined in some detail. Metabolic acidosis acutely increases the kinetic activity of NHE3 through direct pH effects and by phosphorylation (8), while chronic acidosis increases the number of NHE3 transporters (9).

Acid-base transporter kinetics cannot account for precise pH sensing

How does the kidney “know” to adjust net acid excretion with such precision with only minimal changes in plasma bicarbonate concentration? Available data in the physiology literature suggests that transporter kinetics alone cannot account for this degree of sensitivity. In the proximal tubule, a reduction in extracellular bicarbonate induces a fall in intracellular pH, which directly activates the sodium/hydrogen exchanger through an intracellular pH regulatory site (10). This requires a change in intracellular pH of about 0.1 to achieve a 50% increase in the rate of transport or an approximately 5% change in the rate of transport in response to a change in extracellular bicarbonate concentration of 1 mM. Both the luminal vacuolar H+-ATPase and the basolateral sodium bicarbonate cotransporter in the proximal tubule are even less responsive to changes in intracellular pH (11–13). This suggests that a bicarbonate (or pH) sensor that can amplify luminal proton secretion must be present.